drug summary · 4 NDC codes
LYTGOBI 4 mg/1
FUTIBATINIB
HUMAN PRESCRIPTION DRUG record from the RxAtlas dataset, marketing status NDA. Facts and NDC codes below are exported values from the current release, not inferred or edited prose.
Facts
Field definitions, types, and provenance rules are in the data dictionary.
| generic name | FUTIBATINIB |
|---|---|
| active ingredients | FUTIBATINIB |
| dosage form | TABLET |
| route | ORAL |
| strength | 4 mg/1 |
| marketing status | NDA |
| DEA schedule | not reported |
| application number | NDA214801 |
| ATC code | not reported |
| RxCUI | not reported |
| manufacturer | TAIHO PHARMACEUTICAL CO., LTD. |
| product type | HUMAN PRESCRIPTION DRUG |
| pharmacologic class | Breast Cancer Resistance Protein Inhibitors [MoA]; Fibroblast Growth Factor Receptor Inhibitors [MoA]; Kinase Inhibitor [EPC]; P-Glycoprotein Inhibitors [MoA] |
NDC codes
4 National Drug Codes are mapped to this product in the current release. Package descriptions are not part of the published export, so the NDC code is the canonical package identifier here.
| NDC | Package description |
|---|---|
| 64842-0120 | — |
| 64842012004 | — |
| 64842012005 | — |
| 64842012006 | — |
Other FUTIBATINIB products
One other product in the current release publishes the same generic name. Strength, dosage form, and labeler are what distinguish them.
- LYTGOBI 16 mg/1TABLET · TAIHO PHARMACEUTICAL CO., LTD.
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access to the full catalogue; credited toward the licence.